Successful immunomodulators for the treatment of COVID-19 have opened the pathway for comparative trials.
作者信息
Gallagher Jason C, Morgan Rebecca L
机构信息
Temple University, School of Pharmacy, Philadelphia, Pennsylvania, USA.
Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada; School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
出版信息
Clin Microbiol Infect. 2023 Jan;29(1):7-9. doi: 10.1016/j.cmi.2022.10.016. Epub 2022 Oct 17.
Abstract
摘要
相似文献
1
Successful immunomodulators for the treatment of COVID-19 have opened the pathway for comparative trials.
Clin Microbiol Infect. 2023 Jan;29(1):7-9. doi: 10.1016/j.cmi.2022.10.016. Epub 2022 Oct 17.
2
Therapeutic role of immunomodulators during the COVID-19 pandemic- a narrative review.免疫调节剂在 COVID-19 大流行期间的治疗作用——叙述性综述。
Postgrad Med. 2022 Mar;134(2):160-179. doi: 10.1080/00325481.2022.2033563. Epub 2022 Feb 12.
3
Effect of tocilizumab, sarilumab, and baricitinib on mortality among patients hospitalized for COVID-19 treated with corticosteroids: a systematic review and meta-analysis.托珠单抗、沙利鲁单抗和巴瑞替尼对 COVID-19 住院患者接受皮质类固醇治疗的死亡率的影响：系统评价和荟萃分析。
Clin Microbiol Infect. 2023 Jan;29(1):13-21. doi: 10.1016/j.cmi.2022.07.008. Epub 2022 Jul 19.
4
COVID-19, steroids and other immunomodulators: The jigsaw is not complete.新型冠状病毒肺炎、类固醇及其他免疫调节剂：拼图尚未完成。
Anaesth Crit Care Pain Med. 2020 Dec;39(6):699-701. doi: 10.1016/j.accpm.2020.10.011. Epub 2020 Oct 25.
5
Nosocomial Infections in COVID-19 Patients Treated with Immunomodulators: A Narrative Review.接受免疫调节剂治疗的COVID-19患者的医院感染：一项叙述性综述。
Front Biosci (Schol Ed). 2022 Sep 26;14(4):26. doi: 10.31083/j.fbs1404026.
6
Choosing immunomodulating therapies for the treatment of COVID-19: recommendations based on placebo-controlled trial evidence.选择免疫调节疗法治疗 COVID-19：基于安慰剂对照试验证据的建议。
Clin Microbiol Infect. 2024 May;30(5):611-618. doi: 10.1016/j.cmi.2023.12.028. Epub 2024 Jan 3.
7
Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.沙利鲁单抗对比标准治疗用于住院 COVID-19 肺炎患者的早期治疗：SARTRE：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Sep 16;21(1):794. doi: 10.1186/s13063-020-04633-3.
8
Combination therapy with remdesivir and immunomodulators improves respiratory status in COVID-19: A retrospective study.瑞德西韦联合免疫调节剂改善 COVID-19 患者的呼吸状况：一项回顾性研究。
J Med Virol. 2022 Dec;94(12):5702-5712. doi: 10.1002/jmv.28037. Epub 2022 Aug 8.
9
A comparison of the effectiveness of different doses of tocilizumab and sarilumab in the treatment of severe COVID-19: a natural experiment due to drug shortages.比较不同剂量托珠单抗和沙利鲁单抗治疗重症 COVID-19 的疗效：由于药物短缺的自然实验。
Int J Infect Dis. 2023 Apr;129:57-62. doi: 10.1016/j.ijid.2023.01.041. Epub 2023 Feb 2.
10
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial.巴瑞替尼治疗 COVID-19 重症或危重症患者的随机、双盲、安慰剂对照、3 期临床试验。
Lancet Respir Med. 2021 May;9(5):522-532. doi: 10.1016/S2213-2600(21)00099-0. Epub 2021 Mar 4.
引用本文的文献
1
Comparison of Tocilizumab vs Baricitinib in Clinical Outcomes Among Hospitalized Patients With COVID-19: Experience From a Public Hospital System in New York City.托珠单抗与巴瑞替尼对新冠住院患者临床结局的比较：来自纽约市一家公立医院系统的经验
Open Forum Infect Dis. 2023 Aug 9;10(8):ofad426. doi: 10.1093/ofid/ofad426. eCollection 2023 Aug.
2
Role of IP-10 to Predict Clinical Progression and Response to IL-6 Blockade With Sarilumab in Early COVID-19 Pneumonia. A Subanalysis of the SARICOR Clinical Trial.IP-10在预测早期新冠肺炎肺炎临床进展及对沙瑞鲁单抗阻断IL-6治疗反应中的作用。SARICOR临床试验的亚组分析。
Open Forum Infect Dis. 2023 Mar 11;10(4):ofad133. doi: 10.1093/ofid/ofad133. eCollection 2023 Apr.
本文引用的文献
1
Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial.托珠单抗与巴瑞替尼治疗 COVID-19 住院患者的疗效比较：一项开放标签、随机对照临床试验。
Clin Microbiol Infect. 2023 Mar;29(3):372-378. doi: 10.1016/j.cmi.2022.10.015. Epub 2022 Oct 20.
2
Effect of tocilizumab, sarilumab, and baricitinib on mortality among patients hospitalized for COVID-19 treated with corticosteroids: a systematic review and meta-analysis.托珠单抗、沙利鲁单抗和巴瑞替尼对 COVID-19 住院患者接受皮质类固醇治疗的死亡率的影响：系统评价和荟萃分析。
Clin Microbiol Infect. 2023 Jan;29(1):13-21. doi: 10.1016/j.cmi.2022.07.008. Epub 2022 Jul 19.
3
Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial.巴瑞替尼联合标准治疗对接受有创机械通气或体外膜肺氧合治疗的 COVID-19 重症住院成年患者的疗效和安全性：一项探索性、随机、安慰剂对照试验。
Lancet Respir Med. 2022 Apr;10(4):327-336. doi: 10.1016/S2213-2600(22)00006-6. Epub 2022 Feb 3.
4
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.COVID-19 重症患者的白细胞介素 6 受体拮抗剂。
N Engl J Med. 2021 Apr 22;384(16):1491-1502. doi: 10.1056/NEJMoa2100433. Epub 2021 Feb 25.
5
The Multidimensional Challenge of Treating Coronavirus Disease 2019 (COVID-19): Remdesivir Is a Foot in the Door.治疗2019冠状病毒病（COVID-19）的多维挑战：瑞德西韦只是迈出了第一步。
Clin Infect Dis. 2021 Dec 6;73(11):e4175-e4178. doi: 10.1093/cid/ciaa1132.
6
Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review.新型冠状病毒病 2019（COVID-19）的病理生理学、传播、诊断和治疗：综述。
JAMA. 2020 Aug 25;324(8):782-793. doi: 10.1001/jama.2020.12839.
7
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19.美国传染病学会关于2019冠状病毒病患者治疗与管理的指南
Clin Infect Dis. 2020 Apr 27. doi: 10.1093/cid/ciaa478.
8
Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options.2019年冠状病毒病的治疗：早期及新出现的治疗选择综述
Open Forum Infect Dis. 2020 Mar 23;7(4):ofaa105. doi: 10.1093/ofid/ofaa105. eCollection 2020 Apr.
Zotero 插件